The Director of Cleveland Clinic’s Leukemia Program argues that we must define trial outcomes that matter to patients.
Mikkael Sekeres, MD, MS, Director of the Leukemia Program at Cleveland Clinic Cancer Center, recently penned an op-ed for ASH Clinical News on the importance of patients in the selection of trial outcomes.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
As editor-in-chief of the news source, Dr. Sekeres argues that many outcomes measured and reported in clinical trials have little to no value to patients in terms of survival or quality of life. He urges fellow clinicians to take Robert Frost’s “road less traveled” while using the Cleveland Browns abysmal 2016 record to identify flaws in oncology outcomes measures.
Read the full editorial here.